[1.] Berumen, L.C., et al., Serotonin Receptors in Hippocampus. The Scientific World Journal, 2012. 2012: p.15.
[2.] Birdsall, T.C., 5-Hydroxytryptophan: A Clinically-Effective Serotonin Precursor. Alternative Medicine Review, 1998. 3(4): p. 271-280.
[3.] Prasad, C., Food, mood and health: a neurobiologic outlook. Brazilian Journal of Medical and Biological Research, 1998. 31: p. 1517-1527.
[4.] Martini, Nath, and Bartholomew, Fundamentals of Anatomy and Physiology. 9th ed, ed. L. Berriman. 2012, San Francisco: Pearson
[5.] Berton, O. and E.J. Nestler, New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci, 2006. 7(2): p. 137-151.
[6.] van Praag, H.M., et al., A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as antidepressant. Psychopharmacologia, 1972. 25(1): p. 14-21.
[7.] Trachte, G.J., T. Uncini, and M. Hinz, Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatric Disease and Treatment, 2009. 5: p. 227-235.
[8.] von Sano, T., L-5-Hydroxytryptophan-(L-5-HTP) Therapie*. Psychiatry and Clinical Neurosciences, 1972. 26(1): p. 7-17.
[9.] Jangid, P., et al., Comparative study of efficacy of l-5-hydroxytryptophan and fluoxtin in patients presenting with first depressive episode. Asian Journal of Psychiatry, 2013. 6(1): p. 29-34.
[10.]Fujiwara, J. and S. Otsuki, Subtype of Affective Psychoses Classified by Response on Amineprecursors and Monoamine Metabolism. Psychiatry and Clinical Neurosciences, 1974. 28(2): p. 93-100.
[11.] Takahashi, S., H. Kondo, and N. Kato, Effect of L-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients. Journal of Psychiatric Research, 1975. 12(3): p. 177-187.
[12.] Nakajima, T., Y. Kudo, and Z. Kaneko, Clinical Evaluation of 5-Hydroxy-L-Tryptophan as an Antidepressant Drug. Psychiatry and Clinical Neurosciences, 1978. 32(2): p. 223-230.
[13.] Alino, J.J., J.L. Gutierrez, and M.L. Iglesias, 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study. Int Pharmacopsychiatry, 1976. 11(1): p. 8-15.
[14.]Pöldinger, W., B. Calanchini, and W. Schwarz, A Functional-Dimensional Approach to Depression: Serotonin Deficiency as a Target Syndrome in a Comparison of 5-Hydroxytryptophan and Fluvxamine. Psychopathology, 1991. 24(2): p. 53-81.
[15.] Bell, E.A. and D.H. Janzen, Medical and Ecological Considerations of L-Dopa and 5-HTP in Seeds. Nature, 1971. 229(5280): p. 136-137.
[16.] Biskup, C.S., et al., Effects of Acute Tryptophan Depletion on Brain Serotonin Function and Concentrations of Dopamine and Norepinphrine in C57BL/6J and BALB/cJ Mice. PLoS ONE, 2012. 7(5): p. e35916.
[17] Mcgill University, Montreal – Psychopharmacology for the Clinician – Journal of Psychiatry Neuroscience 2007; 32(3)
[18] a b c Glaeser BS, et al. Elevation of plasma tyrosine after a single oral dose of L-tyrosine. Life Sci. (1979)
[19] Soranzo et al Fear expression is suppressed by tyrosine administration – Journal of Nature Scientific reports 9, 16073 (2019)